Tielemans Susanne M A J, de Melker Hester E, Hahné Susan J M, Boef Anna G C, van der Klis Fiona R M, Sanders Elisabeth A M, van der Sande Marianne A B, Knol Mirjam J
Centre for Infectious Disease Control, National Institute for Public Health and the Environment, 3720 BA Bilthoven, Netherlands.
Department of Paediatrics, University Medical Centre Utrecht, Utrecht, Netherlands.
BMJ. 2017 Aug 30;358:j3862. doi: 10.1136/bmj.j3862.
To investigate whether measles, mumps, and rubella (MMR) vaccine has positive non-specific effects in a high income setting and to compare rates of hospital admissions for infections between children aged ≤2 years who received live MMR vaccine and those who received an inactivated vaccine against diphtheria, tetanus, pertussis, polio, and type b (DTaP-IPV-Hib) as their most recent vaccination. Nationwide population based cohort study. In the Netherlands, DTaP-IPV-Hib+pneumococcal vaccination (PCV) is recommended at ages 2, 3, 4, and 11 months and MMR + meningococcal C (MenC) vaccination at age 14 months. Data from the national vaccine register were linked to hospital admission data. 1 096 594 children born in 2005-11 who received the first four DTaP-IPV-Hib+PCV vaccines. Hazard ratio for admission to hospital for infection in children with MMR+MenC compared with the fourth DTaP-IPV-Hib+PCV as their most recent vaccination. Cox regression was performed with most recent vaccination as time dependent variable, adjusted for potential confounders. Analyses were repeated with admission for injuries or poisoning as a negative control outcome. In addition, rate of admission for infection was compared between the fourth and third DTaP-IPV-Hib+PCVas most recent vaccination. Having had MMR+MenC as the most recent vaccination was associated with a hazard ratio of 0.62 (95% confidence interval 0.57 to 0.67) for admission to hospital for infection and 0.84 (0.73 to 0.96) for injuries or poisoning, compared with the fourth DTaP-IPV-Hib+PCV as most recent vaccination. The fourth DTaP-IPV-Hib+PCV as most recent vaccination was associated with a hazard ratio of 0.69 (0.63 to 0.76) for admission to hospital for infection, compared with the third DTaP-IPV-Hib+PCV as most recent vaccination. Healthy vaccinee bias could at least partly explain the observed lower rate of admission to hospital with infection after MMR vaccination. The lower rate is associated with receipt of any additional vaccine, not specifically MMR vaccine. This emphasises the caution required in the interpretation of findings from observational studies on non-specific effects of vaccination.
为调查麻疹、腮腺炎和风疹(MMR)疫苗在高收入环境中是否具有积极的非特异性效果,并比较≤2岁接种MMR活疫苗的儿童与接种白喉、破伤风、百日咳、脊髓灰质炎和b型流感嗜血杆菌(DTaP-IPV-Hib)灭活疫苗作为最近一次疫苗接种的儿童之间的感染住院率。基于全国人群的队列研究。在荷兰,建议在2、3、4和11个月龄时接种DTaP-IPV-Hib+肺炎球菌疫苗(PCV),在14个月龄时接种MMR+脑膜炎球菌C(MenC)疫苗。国家疫苗登记数据与住院数据相关联。2005年至2011年出生的1096594名儿童接种了前四剂DTaP-IPV-Hib+PCV疫苗。以MMR+MenC作为最近一次疫苗接种的儿童与以第四剂DTaP-IPV-Hib+PCV作为最近一次疫苗接种的儿童相比,感染住院的风险比。以最近一次疫苗接种作为时间依赖性变量进行Cox回归,并对潜在混杂因素进行调整。以受伤或中毒住院作为阴性对照结果重复分析。此外,比较了以第四剂DTaP-IPV-Hib+PCV和第三剂DTaP-IPV-Hib+PCV作为最近一次疫苗接种的儿童的感染住院率。与以第四剂DTaP-IPV-Hib+PCV作为最近一次疫苗接种相比,以MMR+MenC作为最近一次疫苗接种的儿童感染住院的风险比为0.62(95%置信区间0.57至0.67),受伤或中毒的风险比为0.84(0.73至0.96)。与以第三剂DTaP-IPV-Hib+PCV作为最近一次疫苗接种相比,以第四剂DTaP-IPV-Hib+PCV作为最近一次疫苗接种的儿童感染住院的风险比为0.69(0.63至0.76)。健康疫苗接种者偏倚至少可以部分解释MMR疫苗接种后观察到的较低感染住院率。较低的比率与接种任何额外疫苗有关,而非特定于MMR疫苗。这强调了在解释疫苗接种非特异性效果的观察性研究结果时需要谨慎。